Akebia Therapeutics (AKBA) EBITDA Margin Growth (5y) (2022 - 2026)
Akebia Therapeutics (AKBA) EBITDA Margin Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11,538.00 |
| Dec 31, 2025 | 37,168.00 |
| Sep 30, 2025 | 39,487.00 |
| Jun 30, 2025 | 21,538.00 |
| Mar 31, 2025 | 9,039.00 |
| Dec 31, 2024 | 29,740.00 |
| Sep 30, 2024 | 52,564.00 |
| Jun 30, 2024 | 18,463.00 |
| Mar 31, 2024 | 10,750.00 |
| Dec 31, 2023 | 17,247.00 |
| Sep 30, 2023 | 2,136.00 |
| Jun 30, 2023 | 79,454.00 |
| Mar 31, 2023 | -1,065.00 |
| Dec 31, 2022 | -2,486.00 |
| Sep 30, 2022 | -4,491.00 |
| Jun 30, 2022 | 10,458.00 |
| Mar 31, 2022 | -7.82 Mn |